<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02188017</url>
  </required_header>
  <id_info>
    <org_study_id>ACPS</org_study_id>
    <nct_id>NCT02188017</nct_id>
  </id_info>
  <brief_title>Acthar Gel for Chronic Pulmonary Sarcoidosis (ACPS)</brief_title>
  <acronym>ACPS</acronym>
  <official_title>ACTHAR Gel for Chronic Pulmonary Sarcoidosis (ACPS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An randomized trial of two maintenance doses of Acthar Gel for patients with chronic&#xD;
      pulmonary sarcoidosis. Patients will be observed for 24 weeks of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center double-blind trial to determine dose and effect size. A total of 20&#xD;
      chronic pulmonary sarcoidosis patients will be recruited at eight clinical sites across the&#xD;
      United States.&#xD;
&#xD;
      After initial evaluation, including pulmonary function, CT and PET scanning, patients will be&#xD;
      randomized to receive 80 Units if Acthar gel daily for 10days, followed by either 40 or 80&#xD;
      units of Acthar gel twice a week for an additional 22 weeks.&#xD;
&#xD;
      At the end of total 24 weeks of treatment, they will undergo repeat evaluation including&#xD;
      pulmonary function, CT, and PET scanning.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steroid toxicity</measure>
    <time_frame>24 weeks</time_frame>
    <description>Cumulative toxicity between two arms of study over 24 weeks of study This will be assessed using a steroid toxicity questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in FVC over course of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chest x-ray</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in chest x-ray</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PET scan</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in lung uptake of PET scan during course of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sarcoidosis Health Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in quality of life as assessed by King's Sarcoidosis Health Questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sarcoidosis</condition>
  <condition>Pulmonary Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>80 units</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80 units ACTHAR gel will be given twice a week for 22 weeks after initial loading</description>
  </arm_group>
  <arm_group>
    <arm_group_label>40 units</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>40 units of ACTHAR gel will be given twice a week for 22 weeks after loading</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar gel</intervention_name>
    <description>Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week</description>
    <arm_group_label>40 units</arm_group_label>
    <arm_group_label>80 units</arm_group_label>
    <other_name>ACTH</other_name>
    <other_name>Cortysin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with biopsy confirmed sarcoidosis meeting American Thoracic Society criteria&#xD;
             23&#xD;
&#xD;
          -  Patient on &gt;5 mg prednisone for pulmonary indications&#xD;
&#xD;
          -  FVC &lt;85% predicted&#xD;
&#xD;
          -  Prednisone dose not reduced in prior 3 months&#xD;
&#xD;
          -  Deterioration of pulmonary disease over the past year&#xD;
&#xD;
          -  Decrease in FVC &gt;5%&#xD;
&#xD;
          -  Age: 18 through 90 (i.e., candidates must have had their 18th birthday, but not had&#xD;
             their 91st birthday).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        adrenal insufficiency (Addison's disease)&#xD;
&#xD;
          -  Scleroderma&#xD;
&#xD;
          -  a fungal infection&#xD;
&#xD;
          -  herpes infection of the eyes&#xD;
&#xD;
          -  osteoporosis&#xD;
&#xD;
          -  a stomach ulcer&#xD;
&#xD;
          -  congestive heart failure&#xD;
&#xD;
          -  high blood pressure&#xD;
&#xD;
          -  recent surgery&#xD;
&#xD;
          -  if you are allergic to pork proteins&#xD;
&#xD;
          -  Do not receive a smallpox vaccine or any &quot;live&quot; vaccine while you are using&#xD;
             corticotropin.&#xD;
&#xD;
          -  Patients receiving anti-Tumor Necrosis Factor antibody (e.g. infliximab, adalimumab)&#xD;
             in prior six months&#xD;
&#xD;
          -  Uncontrolled diabetes, hypertension, or other contra-indication to increased dosage of&#xD;
             glucocorticoids&#xD;
&#xD;
          -  Patients requiring therapy for pulmonary hypertension&#xD;
&#xD;
          -  Females of childbearing potential who are known to be pregnant and/or lactating or who&#xD;
             have a positive urine pregnancy test on screening.&#xD;
&#xD;
          -  Current participation in another research drug treatment protocol (patient cannot&#xD;
             start another experimental agent until after 90 days)&#xD;
&#xD;
          -  Any other condition that the investigator feels would pose a significant hazard to the&#xD;
             patient if Acthar Gel therapy is initiated.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert P Baughman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robert P Baughman, MD</last_name>
    <phone>513-58405225</phone>
    <email>bob.baughman@uc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felicia Thompson</last_name>
      <phone>513-584-6252</phone>
      <email>THOMPSFA@ucmail.uc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert P Baughman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>April 24, 2014</study_first_submitted>
  <study_first_submitted_qc>July 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>December 4, 2015</last_update_submitted>
  <last_update_submitted_qc>December 4, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Robert P Baughman</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>prednisone, methotrexate, sarcoidosis, azathioprine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis, Pulmonary</mesh_term>
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>May 1, 2017</submitted>
    <returned>May 30, 2017</returned>
    <submitted>February 1, 2018</submitted>
    <returned>February 28, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

